IRIS - Res&Arch Institutional Research Information System - Research & Archive

METRO, GIULIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.195
AS - Asia 4.072
EU - Europa 2.361
SA - Sud America 1.322
Continente sconosciuto - Info sul continente non disponibili 350
AF - Africa 164
OC - Oceania 4
Totale 13.468
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.814
SG - Singapore 1.623
BR - Brasile 973
CN - Cina 613
IT - Italia 611
VN - Vietnam 565
HK - Hong Kong 424
RU - Federazione Russa 349
IE - Irlanda 302
KR - Corea 261
FR - Francia 232
DE - Germania 212
AR - Argentina 142
BD - Bangladesh 142
CA - Canada 134
GB - Regno Unito 118
FI - Finlandia 117
IN - India 103
SE - Svezia 98
MX - Messico 66
EC - Ecuador 59
RO - Romania 59
ZA - Sudafrica 47
AT - Austria 46
ID - Indonesia 46
TR - Turchia 40
IQ - Iraq 39
CO - Colombia 38
UA - Ucraina 35
NL - Olanda 34
JP - Giappone 33
PL - Polonia 33
MA - Marocco 31
VE - Venezuela 31
CR - Costa Rica 30
HN - Honduras 28
PY - Paraguay 28
PK - Pakistan 27
GT - Guatemala 26
ES - Italia 25
SA - Arabia Saudita 22
CL - Cile 19
JM - Giamaica 18
UZ - Uzbekistan 18
DZ - Algeria 17
JO - Giordania 16
CW - ???statistics.table.value.countryCode.CW??? 15
EG - Egitto 15
PH - Filippine 15
SV - El Salvador 15
TT - Trinidad e Tobago 15
PR - Porto Rico 14
MY - Malesia 13
GP - Guadalupe 12
PE - Perù 12
TN - Tunisia 12
CH - Svizzera 11
HR - Croazia 11
LT - Lituania 11
NI - Nicaragua 11
OM - Oman 11
UY - Uruguay 11
LB - Libano 9
SC - Seychelles 9
AE - Emirati Arabi Uniti 8
BO - Bolivia 8
IL - Israele 8
CZ - Repubblica Ceca 7
KE - Kenya 7
AL - Albania 6
ET - Etiopia 6
KZ - Kazakistan 6
AZ - Azerbaigian 5
BE - Belgio 5
HU - Ungheria 5
PS - Palestinian Territory 5
BH - Bahrain 4
BY - Bielorussia 4
DO - Repubblica Dominicana 4
NP - Nepal 4
PT - Portogallo 4
AO - Angola 3
BB - Barbados 3
BG - Bulgaria 3
DK - Danimarca 3
EE - Estonia 3
GR - Grecia 3
LV - Lettonia 3
MT - Malta 3
NG - Nigeria 3
AU - Australia 2
BA - Bosnia-Erzegovina 2
CM - Camerun 2
EU - Europa 2
KG - Kirghizistan 2
KH - Cambogia 2
MK - Macedonia 2
RS - Serbia 2
SN - Senegal 2
SO - Somalia 2
Totale 13.109
Salva come PNG Salva come JPEG
Città #
Singapore 1.087
Ashburn 607
San Jose 543
Hong Kong 419
Chandler 331
Dublin 300
Seoul 260
Council Bluffs 252
Santa Clara 197
Ho Chi Minh City 187
Perugia 168
Lauterbourg 155
Beijing 137
Piscataway 130
Boardman 125
Moscow 125
New York 125
Los Angeles 107
San Mateo 104
Hanoi 98
São Paulo 97
Munich 92
Princeton 73
Altamura 72
Dallas 59
Lawrence 58
Medford 58
Bucharest 57
Dong Ket 57
North Bergen 54
Hefei 48
Turku 44
Helsinki 43
Wilmington 41
Chicago 40
The Dalles 35
Milan 34
Riverbank 34
Charlotte 33
Rome 33
Rio de Janeiro 31
Andover 30
Brooklyn 30
Tokyo 30
Frankfurt am Main 29
Mexico City 29
Montreal 29
Nuremberg 28
Atlanta 27
Orem 27
Redmond 27
Brasília 25
Da Nang 25
Denver 25
New Orleans 25
Warsaw 25
Guatemala City 23
San José 23
Guayaquil 22
Johannesburg 22
Stockholm 21
Haiphong 20
Naples 20
Toronto 20
Buffalo 19
Baghdad 18
Poplar 18
Belo Horizonte 17
Boston 17
Guarulhos 17
Buenos Aires 16
Falkenstein 16
London 16
Phoenix 16
San Paolo di Civitate 16
Amman 15
Saint Petersburg 15
Seattle 15
Tashkent 15
Biên Hòa 14
Bologna 14
Chennai 14
Curitiba 14
Manchester 14
Vienna 14
Willemstad 14
Amsterdam 13
Guangzhou 13
Quito 13
Shanghai 13
Houston 12
Mumbai 12
San Salvador 12
Santo André 12
Bắc Ninh 11
Caracas 11
Hải Dương 11
Osijek 11
San Pedro Sula 11
Tegucigalpa 11
Totale 7.642
Salva come PNG Salva come JPEG
Nome #
Assessment of TILs, IDO-1, and PD-L1 in resected non-small cell lung cancer: an immunohistochemical study with clinicopathological and prognostic implications 206
New somatic TERT promoter variants enhance the Telomerase activity in Glioblastoma 155
Efficacy of Pembrolizumab Monotherapy in Patients with or without Brain Metastases from Advanced Non-Small Cell Lung Cancer with a PD-L1 Expression ≥50% 135
Gene identification for risk of relapse in stage I lung adenocarcinoma patients: A combined methodology of gene expression profiling and computational gene network analysis 133
Alectinib's activity against CNS metastases from ALK-positive non-small cell lung cancer: a single institution case series 133
Indoleamine 2,3-Dioxygenase 2 Immunohistochemical Expression in Resected Human Non-small Cell Lung Cancer: A Potential New Prognostic Tool 131
Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy 131
Identification of EML4-ALK Rearrangement and MET Exon 14 R988C Mutation in a Patient with High-Grade Neuroendocrine Lung Carcinoma Who Experienced a Lazarus Response to Crizotinib 127
MAPK Pathway-Activating Alteration and Immunotherapy Efficacy in Squamous Cell Lung Carcinoma: Results from the Randomized, Prospective SQUINT Trial 126
Large Cell Neuroendocrine Carcinoma Transformation and EGFR-T790M Mutation as Coexisting Mechanisms of Acquired Resistance to EGFR-TKIs in Lung Cancer 126
Higher tlr7 gene expression predicts poor clinical outcome in advanced nsclc patients treated with immunotherapy 119
Anaplastic lymphoma kinase immunohistochemistry scores do not predict sensitivity to crizotinib in fluorescence in situ hybridization-positive non-small cell lung cancer patients. 118
Non-coding RNAs in lung cancer 117
Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib 116
Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study 115
Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 >= 50% who progress on first-line immunotherapy: real-world data from a European cohort 113
Future options for ALK-positive non-small cell lung cancer 108
Osimertinib 106
High PD-L1/IDO-2 and PD-L2/IDO-1 Co-Expression Levels Are Associated with Worse Overall Survival in Resected Non-Small Cell Lung Cancer Patients 106
Prognostic implication of aquaporin 1 overexpression in resected lung adenocarcinoma 105
Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy 104
CT-Guided Percutaneous Trans-scapular Lung Biopsy in the Diagnosis of Peripheral Pulmonary Lesion Nodules of the Superior Lobes Using Large Needles 102
Long-term survival with erlotinib in advanced lung adenocarcinoma harboring synchronous EGFR G719S and KRAS G12C mutations 101
Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer 101
KRAS mutation and DNA repair and synthesis genes in non-small-cell lung cancer 101
Optimizing the risk stratification of astrocytic tumors by applying the cIMPACT-NOW Update 3 signature: real-word single center experience 99
KRAS mutational status and sensitivity to a reversible epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in EGFR wild type (WT) advanced non-small cell lung cancer (NSCLC) patients (pts) 99
Fatal acute disseminated intravascular coagulation as presentation of advanced ALK-positive non-small cell lung cancer: Does oncogene addiction matter? 99
Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab 99
Lorlatinib beyond progression plus platinum/pemetrexed for ALK-positive non-small cell lung cancer patients: report of two cases 98
Years of sorafenib investigation in advanced non-small cell lung cancer: is there a 'NExUS' linking an unsuccessful treatment and a potentially active one? 98
Targeting the KRAS variant for treatment of non-small cell lung cancer: Potential therapeutic applications 98
Inflammatory markers as prognostic factors of survival in patients affected by hepatocellular carcinoma undergoing transarterial chemoembolization 98
Role of Expression Levels of Fabp3, H19, Tfpi2, Ark1b1 Cyp3a5, Scgb3a2 Genes In Adenocarcinoma Stage I Patients. 96
Clinical Outcome With Platinum-Based Chemotherapy in Patients With Advanced Nonsquamous EGFR Wild-Type Non-Small-Cell Lung Cancer Segregated According to KRAS Mutation Status. 96
Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumab 95
Targeting EGFR and ALK in NSCLC: current evidence and future perspective 95
Sacrum colon-rectal cancer metastasis: Microwave ablation for palliative pain treatment 95
Ercc1 Mrna Expression and Kras Mutation Status In Egfr Wild Type (wt) Advanced Non-small Cell Lung Cancer (nsclc) Patients 94
UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN) 94
Selumetinib: a promising pharmacologic approach for KRAS-mutant advanced non-small-cell lung cancer 92
Identification of Targetable Driver Mutations In Molecularly Selected Never Smoker Lung Adenocarcinomas 91
Treatment of metastatic non-small cell lung cancer: 2018 guidelines of the Italian Association of Medical Oncology (AIOM) 91
Successful Response to Osimertinib Rechallenge after Intervening Chemotherapy in an EGFR T790M-Positive Lung Cancer Patient. 91
Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice 90
How might treatment of ALK-positive non-small cell lung cancer change in the near future? 90
MiRNAs and resistance to EGFRâ€"TKIs in EGFR-mutant non-small cell lung cancer: Beyond 'traditional mechanisms' of resistance 90
Repotrectinib’s Clinical Benefit and Its Brain Penetration in a Patient with Meningeal Carcinomatosis from G2032R-Mutated ROS-1 Positive Non-Small Cell Lung Cancer 89
Tumour infiltrating lymphocytes (TILs) and PD-L1 expression in malignant pleural mesothelioma. 89
Malignant giant solitary fibrous tumor of the pleura metastatic to the thyroid gland 89
Sensitivity to immune checkpoint blockade in advanced non-small cell lung cancer patients with EGFR exon 20 insertion mutations 89
Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype 88
Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer 87
Detection of egfr mutations in plasma cell-free tumor dna of tki-treated advanced-nsclc patients by three methodologies: Scorpion-arms, pnaclamp, and digital pcr 87
Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study 86
Enteric-type adenocarcinoma of the lung harbouring a novel KRAS Q22K mutation with concomitant KRAS polysomy: A case report 86
Prognosis of ALK-rearranged non-small-cell lung cancer patients carrying TP53 mutations 84
Concomitant TP53 Mutation Confers Worse Prognosis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs 84
Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis 84
Aromatase inhibitors in post-menopausal metastatic breast carcinoma 80
Advanced non-small-cell lung cancer: how to manage non-oncogene disease 80
Correction: Repotrectinib’s Clinical Benefit and Its Brain Penetration in a Patient with Meningeal Carcinomatosis from G2032R-Mutated ROS-1 Positive Non-Small Cell Lung Cancer (Oncology and Therapy, (2024), 12, 1, (163-171), 10.1007/s40487-023-00251-6) 80
Upfront pembrolizumab as an effective treatment start in patients with PD-L1 ≥ 50% non-oncogene addicted non-small cell lung cancer and asymptomatic brain metastases: an exploratory analysis 80
Brigatinib for anaplastic lymphoma kinase-tyrosine kinase inhibitor naïve anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: An effective but still broken option 80
RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion 79
HER2 Protein and Gene Variation between Primary and Metastatic Breast Cancer: Significance and Impact on Patient Care 79
Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence 79
[Management of small cell lung cancer patient in the regions of Lazio, Umbria and Sardinia.] 78
Clinical impact of sequential treatment with ALK-TKIs in patients with advanced ALK-positive non-small cell lung cancer: Results of a multicenter analysis 77
A prospective study on clinicians' attitudes and survival outcomes for patients with advanced NSCLC and poor performance status in the immunotherapy era: PICASO (GOIRC-04-2020) 76
Clinical experience with gefitinib: an update 76
Emerging drugs for small cell lung cancer - an update 76
Perspectives on salvage therapy for non-small-cell lung cancer 75
APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research 75
Advances on EGFR mutation for lung cancer 75
An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy-EDEN trial GOIRC 04-2016 74
RET Rearrangement as a Predictor of Unresponsiveness to Immunotherapy in Non-Small Cell Lung Cancer: Report of Two Cases with Review of the Literature 74
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry 74
Resistance to TKIs in EGFR-Mutated Non-Small Cell Lung Cancer: From Mechanisms to New Therapeutic Strategies 73
Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease 73
Navigating challenges in EGFR exon 20 insertions: The PAPILLON trial unravels the promise of amivantamab-chemotherapy 71
Inflamed Tumor Phenotype as Predictor of Long-Term Response to Pembrolizumab in an EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Patient with Acquired Resistance to Afatinib: a Case Report and Review of the Literature 71
Development of gemcitabine in non-small cell lung cancer: the Italian contribution 70
Assessment of PTEN and PI3K Status in Primary Breast Cancer and Corresponding Metastases: Is It Worthwhile? 70
The Role of Performance Status in Small-Cell Lung Cancer in the Era of Immune Checkpoint Inhibitors 68
Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC 68
Non-small-cell lung cancer: how to manage ALK-, ROS1- and NTRK-rearranged disease 68
Immune checkpoint inhibitors for unresectable malignant pleural mesothelioma 68
MYC and human telomerase (TERC) gene copy number gain in resected non-small cell lung cancer (NSCLC) 67
Is There a Role for Multiple Lines of Anti-HER2 Therapies Administered Beyond Progression in HER2-Mutated Non-Small Cell Lung Cancer? A Case Report and Literature Review 66
Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer 66
ASTRIS: a global real-world study of osimertinib in >3000 patients with EGFR T790M positive non-small-cell lung cancer 66
Abstract 5134: Immunohistochemistry expression of membrane targets for novel therapeutic agents in RET-rearranged NSCLC 65
Expert consensus on perioperative treatment for non-small cell lung cancer 65
Molecular Epidemiology and Treatment Patterns of Patients With EGFR Exon 20-Mutant NSCLC in the Precision Oncology Era: The European EXOTIC Registry 65
Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial 65
Non-small-cell lung cancer: how to manage RET-positive disease 64
Assessment of TILs, IDO-1 and PD-L1 in resected non small cell lung cancer: an immunohistochemical study with clinicopathological and prognostic implications. 64
2356P The role of pathological features in predicting prognosis of patients with advanced RET-positive NSCLC 64
Non-small cell lung cancer: an update on emerging EGFR-targeted therapies 63
Totale 9.112
Salva come PNG Salva come JPEG
Categoria #
all - tutte 58.011
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 58.011
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022389 0 0 0 0 6 6 1 146 30 49 65 86
2022/20231.023 59 214 23 82 95 84 0 38 386 2 30 10
2023/2024459 23 43 30 9 2 3 107 11 26 13 93 99
2024/20251.688 24 96 66 53 139 75 44 125 179 55 579 253
2025/20266.750 399 735 617 1.385 668 366 823 371 570 478 188 150
2026/20272.466 221 267 410 1.304 264 0 0 0 0 0 0 0
Totale 13.468